Xi'an Tianlong Technology Co., Ltd. (hereinafter referred to as "Tianlong Technology") is an innovation driven high-tech enterprise that takes the market as the guide, industry university research as the foundation, and pursues independent brands. Since its establishment in 1997, the company has always adhered to the development concept of technology serving the public, market-oriented, and customer-centric. It is committed to the research and development, production, and overall solution provision of instruments and in vitro diagnostic reagents in the fields of genetic testing and molecular diagnostics. As one of the innovative leaders in the fields of genetic testing and molecular diagnosis in China, the company has achieved sustainable development value. In 2012, it received investment support from SK multinational enterprise group, ranked 57th in the Fortune Global 500. In 2018, it received strategic investment from Shanghai Kehua Biotechnology Co., Ltd. (referred to as Kehua Biotechnology, stock code: 002022), a listed company. In the future, Tianlong Technology and Kehua Biotechnology will deepen their cooperation in product lines, channels, markets, and after-sales services in the field of molecular diagnostics, achieving strategic complementarity and jointly building a world-class molecular diagnostics enterprise. The company has several major technology platforms, including automated nucleic acid extraction, gene amplification, fluorescence PCR, sequencing technology, ATP fluorescence detection, etc. Based on the existing technology platforms, it has achieved the research and development, production, and sales of various products. We have obtained over 50 NMPA (formerly CFDA) registration certificates for medical devices, 7 CE and CB certifications, 4 Korean FDA registration certificates, 5 national key new product certificates, and passed ISO9001 and 13485 quality system assessments. The company's products currently cover molecular detection equipment such as nanomagnetic bead nucleic acid extraction devices, gene amplification thermal cycling devices, real-time fluorescence quantitative PCR devices, and large-scale automated nucleic acid workstations. There are hundreds of supporting reagent varieties, serving the detection and diagnosis of infectious diseases, genetic diseases, tumors, and precision medicine. It has become an independent research and development production enterprise with a complete range of varieties and high market share in the domestic nucleic acid molecular diagnosis industry. The company is also a national high-tech enterprise, a national intellectual property pilot enterprise, a demonstration enterprise for the industrialization of biomedical engineering by the National Development and Reform Commission, an innovative enterprise in Shaanxi Province and Xi'an City, an academician workstation in Shaanxi Province and Xi'an City, and a supporting unit of the Shaanxi Life Science Testing Instrument Engineering Technology Research Center. It has successively led and led more than ten national major scientific instrument and equipment development projects, the National 863 Program, the National Key R&D Program, the National Science and Technology Support Program, as well as provincial and municipal major scientific research and industrialization projects. At the same time, it has undertaken and participated in the development and implementation of multiple projects. The company's products have made important contributions to hepatitis, AIDS, hand, foot and mouth disease, bird flu, eugenics, food safety testing and public health emergencies, and have received extensive attention from leaders at all levels. In 2009, the company's fluorescence quantitative PCR instrument detected the first case of H1N1 influenza in Shaanxi province; In 2012, thousands of handheld ATP fluorescence detectors won the bid from the food safety department; During the prevention and control of human infection with H7N9 avian influenza in 2013, the company's fluorescent quantitative PCR instrument, nucleic acid extractor and reagents were equipped with the First Affiliated Hospital of Zhejiang University, several provincial and municipal CDC and hospitals in Shaanxi, Gansu, Hubei, Jiangsu, and Beijing, and completed the extraction and screening of H7N9 virus nucleic acid from thousands of suspected influenza samples. CCTV News Network and the official website of the Ministry of Science and Technology carried out special reports; In 2013, the fluorescence quantitative PCR instrument won a large number of bids in medical and CDC systems in multiple provinces. The company has applied for more than 20 intellectual property rights such as invention patents for its products, won six provincial and ministerial level scientific and technological awards, and its achievements have been selected for the "National 11th Five Year Plan Major Scientific and Technological Achievements Exhibition" and "12th Five Year Plan Scientific and Technological Innovation Achievements Exhibition". Vice Premier Liu Yandong, Minister Wan Gang, Vice Minister Hou Jianguo and others personally visited the exhibition booth. In 2014, the Ebola epidemic ravaged West Africa, and the company quickly responded by developing and producing Ebola virus nucleic acid testing reagents using its own reserves of invention patents such as ultra sensitive molecular diagnostics. This reagent kit has undergone strict assessment by NMPA, passed emergency approval, and obtained the national NMPA registration certificate, officially listed as an emergency reserve product for diagnosing Ebola virus and epidemic prevention and control in China and West Africa. In June 2015, there was an outbreak of Middle East Respiratory Syndrome (MERS) in South Korea. The company was the first to successfully develop MERS detection reagents and export them to South Korea, which were sent to several provincial CDCs and hospitals in China for initial screening of influenza samples and fever patients in the National Influenza Surveillance Network Center and designated hospitals. In June 2016, Liu Yandong, member of the Political Bureau of the Central Committee and Vice Premier of the State Council, conducted research on the national innovation driven development strategy and people's livelihood healthcare reform in Jiangsu. Professor Peng Niancai, the founder of the company and a national science and technology innovation and entrepreneurship talent, gave a product function demonstration and reported on his work. In 2017, the company's fluorescence quantitative PCR instrument and reagents detected the first case of H7N9 human avian influenza in Shaanxi. In 2018, the African swine fever outbreak occurred in China. Our company has equipped thousands of nucleic acid extraction equipment, fluorescent quantitative PCR equipment, and supporting reagents with multiple national and provincial animal disease control centers, hundreds of food enterprises and research institutions, such as COFCO Group, Shuanghui Group, New Hope Group, etc., to fully ensure food safety. At the end of 2019, the COVID-19 broke out in Wuhan and quickly spread across the country. The COVID-19 nucleic acid testing reagents and related testing equipment developed by Tianlong Technology quickly were sent to CDC and medical institutions in Hubei Province at the first time, and then more than 500 national, provincial and municipal CDC and medical institutions continued to purchase hundreds of Tianlong equipment and millions of reagents, and the first positive case was detected in Shaanxi Province, Yunnan Province, Sichuan Province and other places. CCTV News Network, Xinhua News Agency, People's Daily and other authoritative media made a series of special reports. We carry the dream of creating healthy lives through technology and contribute to China's public health epidemic prevention and control work! The company always puts talent strategy first, adhering to the concept of "ability, attitude and quality are both important, education and qualifications are not important", and has built a scientific research, marketing and management team led by industry and discipline leaders with strong action capabilities in industry development, industrial operation, core technology and other aspects. With the development of the market and the continuous enrichment of the company's products, the company has established multiple business units such as Clinical Division, Life Science Division, Overseas Division, Custody and Regional Co construction Project Department, and Individualized Medication Project Department. Through various flexible cooperation models such as distributors and direct sales, the products have now been distributed throughout the country and exported overseas, providing high-quality products and services to global users. We will continue to focus on customer needs, respond quickly, and provide increasingly comprehensive services and excellent products to serve fields such as medical diagnosis, scientific research, biological testing, personalized medicine, independent laboratories, food safety, and inspection and quarantine. In the face of future opportunities and challenges, we will work together with all sectors in a more open manner to establish a national brand as Tianlong's mission, create first-class molecular diagnostic products, and continuously strive for human health. The all-new Tianlong will continue to uphold the spirit of excellence, self-improvement, honor, and responsibility with the responsibility and sentiment of a corporate citizen, and make unremitting efforts to build Tianlong into an internationally renowned enterprise in the field of molecular diagnostics!